Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Droperidol for Cannabinoid Hyperemesis Syndrome
NCT05244460Phase 3Unknown
- Sponsor
- Mercy
- Start
- Dec 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of droperidol in Cannabinoid hyperemesis syndrome (CHS), sponsored by Mercy. Status: unknown.
02
Drugs
droperidol
03
Conditions
Cannabinoid hyperemesis syndrome (CHS)
Beyond the preview
Go deeper on NCT05244460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05244460.